Price T Rowe Associates Inc Pharma Cyte Biotech, Inc. Put Options Transaction History
Price T Rowe Associates Inc
- $867 Billion
- Q4 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding PMCB
# of Institutions
27Shares Held
706KCall Options Held
9.3KPut Options Held
4.6K-
Vanguard Group Inc Valley Forge, PA192KShares$319,3620.0% of portfolio
-
Geode Capital Management, LLC Boston, MA165KShares$273,4610.0% of portfolio
-
Ayrton Capital LLC Westport, CT92.1KShares$152,8647.31% of portfolio
-
Equitec Proprietary Markets, LLC82.7KShares$137,3260.07% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny49.3KShares$81,8380.0% of portfolio
About PharmaCyte Biotech, Inc.
- Ticker PMCB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 20,750,100
- Market Cap $34.4M
- Description
- PharmaCyte Biotech, Inc., a biotechnology company, focuses on developing and commercializing cellular therapies for cancer, diabetes, and malignant ascites in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types o...